Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Advanced Magnetics Announces Retirement of Founder Jerome Goldstein

Abstract:
Advanced Magnetics,Inc. (Nasdaq: AMAG) today announced that Jerome Goldstein, the Executive
Chairman of the Board of Directors and founder of the company, will retire
as an officer and director of the company effective May 1, 2007. The
company's Board of Directors voted to confer on Mark Skaletsky, a member of
the Board of Directors, the role of Chairman of the Board effective as of
Mr. Goldstein's retirement.

Advanced Magnetics Announces Retirement of Founder Jerome Goldstein

CAMBRIDGE, MA | Posted on April 2nd, 2007

Mr. Goldstein founded Advanced Magnetics in November 1981 and completed
its initial public offering in June 1986. Mr. Goldstein commented that "For
25 years, we have developed our iron oxide nanoparticle technology for the
benefit of patients. Two early products, Feridex I.V.(R) and GastroMARK(R),
were brought to market and two additional products, Combidex(R) and
ferumoxytol, both of which I believe could have major beneficial impact,
are in the wings. We have succeeded in putting together an excellent team
capable of accomplishing the company's objectives going forward. I am 68
years old and the time and situation are appropriate for me to pass the
baton on to Brian Pereira. I wish all the employees of Advanced Magnetics
continued success."

Advanced Magnetics' President and Chief Executive Officer, Brian J. G.
Pereira, MD stated, "Jerry's vision and entrepreneurship led to the
founding of Advanced Magnetics and the development of outstanding
diagnostic and therapeutic products with the potential to significantly
improve patients' lives. He has guided the company ably for 25 years and
has been a vital contributor to its success to date, while positioning the
company well for future success. We thank Jerry for his invaluable
contributions over the years and wish him well in his plans for the
future."

####

About Advanced Magnetics
Advanced Magnetics, Inc. is a developer of superparamagnetic iron oxide
nanoparticles used in pharmaceutical products. As a leader in our field, we
are dedicated to the development and commercialization of our proprietary
nanoparticle technology for use in therapeutic iron compounds to treat
anemia, as well as novel imaging agents to aid in the diagnosis of
cardiovascular disease and cancer.

Ferumoxytol, the company's key product candidate, is being developed
for use as an intravenous iron replacement therapeutic for the treatment of
iron deficiency anemia in chronic kidney disease. The company plans to file
a New Drug Application for marketing approval of ferumoxytol with the U.S.
Food and Drug Administration during the fourth calendar quarter of 2007.

Combidex(R), the company's second product under development, is an
investigational functional molecular imaging agent consisting of iron oxide
nanoparticles for use in conjunction with magnetic resonance imaging, or
MRI, to aid in the differentiation of cancerous from normal lymph nodes. In
March 2005, the company received an approvable letter from the FDA with
respect to Combidex, subject to certain conditions.

For more information about us, please visit our website at
http://www.advancedmagnetics.com , the content of which is not part of this
press release.

This document contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and federal securities
laws. Any statements contained in this press release that do not describe
historical facts, including but not limited to, statements regarding the
potential beneficial impact of Combidex(R) and ferumoxytol and their
potential for significantly improving patients' lives, the company's
potential accomplishment of its objectives going forward and its potential
future successes, are forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially from
those discussed in such forward-looking statements. Such risks and
uncertainties include the following: (1) the possibility that we may not be
able to successfully complete the development of ferumoxytol, or may not be
able to complete the development in a timely or cost-effective manner, due
to deficiencies in the design or oversight by us of these trials, the
failure of our trials to demonstrate that ferumoxytol is safe and
efficacious, unexpected results from our clinical sites, inadequate
performance by third-party service providers involved in the conduct of the
clinical trials, or any other factor causing an increase in expenses, a
delay and/or a negative effect on the results of the clinical studies for
ferumoxytol; (2) uncertainties surrounding the our ability to obtain
regulatory approval for ferumoxytol from the FDA; (3) the possibility that
the results of past ferumoxytol studies may not be replicated in future
studies; (4) the fact that we have limited sales and marketing expertise;
(5) uncertainties relating to our patents and proprietary rights; and (6)
other risks identified in our Securities and Exchange Commission filings.
We caution readers not to place undue reliance on any forward-looking
statements which speak only as of the date they are made. We disclaim any
obligation to publicly update or revise any such statements to reflect any
change in expectations or in events, conditions or circumstances on which
any such statements may be based, or that may affect the likelihood that
actual results will differ from those set forth in the forward-looking
statements.

For more information, please click here

Contacts:
Investors:

(617) 498-3361

Media:

(978) 463-7952

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Malaysian Nanotechnology Company Nanopac Innovation Ltd. lists on the NSX January 19th, 2015

Aspen Aerogels, Inc. to Present at the Needham Growth Conference January 8th, 2015

Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin™ Platform for Cancer Therapeutics: Company’s Technology and Expertise in Cancer R&D Evolve to Create New Class of Miniaturized Biologic Drug Conjugates (mBDCs) Encapsulated in Nanoparticles January 8th, 2015

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 2, 2015 January 7th, 2015

Announcements

Advantest to Exhibit at SEMICON Korea in Seoul, South Korea February 4-6 Showcasing Broad Portfolio of Semiconductor Products, Technologies and Solutions January 29th, 2015

Park Systems Announces Innovations in Bio Cell Analysis with the Launch of Park NX-Bio, the only 3-in-1 Imaging Nanoscale Tool Available for Life Science Researchers January 29th, 2015

2015 Nanonics Image Contest January 29th, 2015

Iranian Scientists Use MOFs to Eliminate Dye Pollutants January 29th, 2015

Human Interest/Art

2015 Nanonics Image Contest January 29th, 2015

OCSiAl supports NanoART Imagery Contest January 23rd, 2015

EnvisioNano: An image contest hosted by the National Nanotechnology Initiative (NNI) January 22nd, 2015

Oxford Instruments Asylum Research Announces AFM Image Contest Winners January 11th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE